![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » ILYPSA COMPLETES TRIAL OF ILY101
ILYPSA COMPLETES TRIAL OF ILY101
April 24, 2006
Ilypsa has completed a Phase I clinical trial for ILY101, a novel phosphate-binding agent that is being developed for the treatment of hyperphosphatemia, a serious complication in patients with chronic kidney disease (CKD) on dialysis.
The study examined the safety and tolerability of single and multiple doses of orally-administered ILY101 in twenty-four healthy volunteers. With the successful completion of Phase I, the company expects to initiate a Phase II study in CKD patients on dialysis.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct